المؤلفون: Sans Pola, Carla

Thesis Advisors: Bosch Gil, Josep Àngel, Danes Carreras, Immaculada, Agustí Escasany, M. Antònia (Maria Antònia)

المصدر: TDX (Tesis Doctorals en Xarxa)

مصطلحات موضوعية: Rituximab, Lupus, Glomerulopaties, Nephropathies, Glomerulopatias, Ciències de la Salut

وصف الملف: application/pdf

URL الوصول: http://hdl.handle.net/10803/691618

المؤلفون: Du, Ying¹ (AUTHOR), Yan, Qi¹ (AUTHOR), Li, Chuan¹ (AUTHOR), Zhu, Wenping^1,2 (AUTHOR), Zhao, Chao¹ (AUTHOR), Hao, Yunfeng¹ (AUTHOR), Li, Lin¹ (AUTHOR), Yao, Dan¹ (AUTHOR), Zhou, Xuan¹ (AUTHOR), Li, Ying¹ (AUTHOR), Dang, Yuting¹ (AUTHOR), Zhang, Rong¹ (AUTHOR), Han, Lin¹ (AUTHOR), Wang, Yuanyuan³ (AUTHOR), Hou, Tao⁴ (AUTHOR), Li, Juan⁵ (AUTHOR), Li, Hailin⁶ (AUTHOR), Jiang, Panpan⁷ (AUTHOR), Wang, Pei⁸ (AUTHOR), Chen, Fenying¹ (AUTHOR)

المصدر: Annals of Clinical & Translational Neurology. Dec2024, p1. 12p. 5 Illustrations.

مصطلحات موضوعية: *CHRONIC inflammatory demyelinating polyradiculoneuropathy, *RITUXIMAB, *CORTICOSTEROIDS, *SUBGROUP analysis (Experimental design), *PROGNOSIS

المؤلفون: Yanxia Cai¹, Yaqin Liu¹, Shiyin Deng¹, Yaqi Luo¹, Liehua Deng² doctorcai126@163.com

المصدر: Alternative Therapies in Health & Medicine. Nov2024, Vol. 30 Issue 11, p136-141. 6p.

مصطلحات موضوعية: *PEMPHIGUS vulgaris, *RITUXIMAB, *META-analysis, *AUTOIMMUNE diseases, *GLUCOCORTICOIDS

المؤلفون: Piehl, Fredrik^1,2,3 (AUTHOR) fredrik.piehl@ki.se, Alping, Peter^1,4 (AUTHOR), Virtanen, Suvi⁴ (AUTHOR), Englund, Simon¹ (AUTHOR), Burman, Joachim⁵ (AUTHOR), Fink, Katharina^1,2 (AUTHOR), Fogdell‐Hahn, Anna¹ (AUTHOR), Gunnarsson, Martin⁶ (AUTHOR), Hillert, Jan¹ (AUTHOR), Langer‐Gould, Annette⁷ (AUTHOR), Lycke, Jan⁸ (AUTHOR), Mellergård, Johan⁹ (AUTHOR), Nilsson, Petra¹⁰ (AUTHOR), Olsson, Tomas¹ (AUTHOR), Salzer, Jonatan¹¹ (AUTHOR), Svenningsson, Anders¹² (AUTHOR), Frisell, Thomas⁴ (AUTHOR)

المصدر: Annals of Neurology. Oct2024, Vol. 96 Issue 4, p678-693. 16p.

مصطلحات موضوعية: *RITUXIMAB, *MULTIPLE sclerosis, *COHORT analysis, *COMPARATOR circuits, *SCIENTIFIC observation

المؤلفون: Boisclair, Mélissa¹ (AUTHOR), Robitaille, Charlotte¹ (AUTHOR), Budhram, Adrian^2,3 (AUTHOR), Kunchok, Amy⁴ (AUTHOR), Chapdelaine, Hugo⁵ (AUTHOR), Létourneau-Guillon, Laurent⁶ (AUTHOR), Macaron, Gabrielle¹ (AUTHOR), Larochelle, Catherine¹ (AUTHOR)

المصدر: Kompass Autoimmun. 2024, Vol. 6 Issue 4, p189-193. 5p.

مصطلحات موضوعية: *STATUS epilepticus, *RITUXIMAB, *ELECTROENCEPHALOGRAPHY

المؤلفون: Celgene Corporation

المصدر: A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 Nov 24;128(21):2510-2516. doi: 10.1182/blood-2016-06-718106. Epub 2016 Oct 3.

المصدر: Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

المصدر: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: Eli Lilly and Company

المصدر: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

المصدر: A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Treatment and Natural History Study of Lymphomatoid Granulomatosis

المصدر: Phase 3, Interventional, Multicentre, Open-label, Randomized Study Comparing Rituximab Plus Zanubrutinib to Rituximab Monotherapy in Previously Untreated, Symptomatic Splenic Marginal Zone Lymphoma (RITZ)

المصدر: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

المصدر: Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)

المصدر: A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Other URLs: http://engagezone.msd.com/ds_documentation.php

المصدر: A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 Mar;13(2):258-264. doi: 10.1016/j.jgo.2021.10.003. Epub 2021 Oct 20.

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

المصدر: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Other URLs: https://www.beigenemedical.com/medical-information-request

المصدر: An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)